ArticleNeurology and therapy2026
Initial Monotherapy and Further Anti-seizure Medication Regimens in Adult Patients with Epilepsy: A Population-Based, Longitudinal, Retrospective Analysis of German Prescription Data.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn Germany, approximately 30% of people with epilepsy do not achieve seizure control with anti-seizure medication (ASM). ASM prescription timing and selection are crucial parameters affecting outcomes; however, the prescription characteristics of patients with refractory epilepsy in Germany are poorly understood. Therefore, understanding the pathways of how patients start their first ASM regimen and change to new ASM regimens could be a crucial step towards optimising therapeutic strategies and reducing the negative consequences of uncontrolled seizures.
methodsA retrospective, population-based analysis was carried out using data from the German IQVIA™ Disease Analyzer (DA) and Longitudinal Prescriptions (LRx) databases. Over a 5-year period from 2018 to 2022, approximately 80% of Statutory Health Insurance (SHI)-reimbursed prescriptions were covered. Filtering processes were used to select and analyse patients treated only for epilepsy, and their prescription journeys.
resultsPrevalence and incidence in the selected group was in line with other reported data. Over a third of patients (36.6%) waited ≥ 1 day to receive their first ASM regimen prescription, and all patients stayed on their first ASM regimen for the longest period. Time to change from first and further regimens was on average > 300 days. Levetiracetam was the most prescribed ASM, and newer ASMs licensed in the past decade had much lower prescriptions. Prescribing differences were observed between specialities. DISCUSSION: This analysis contributes to the understanding of current epilepsy treatment shortfalls, showing delays in time to treatment and time to regimen change, and relatively low use of more recent ASMs. Additional work is required to evaluate how much improvement in outcome could be achieved by advancing first prescription timing and ASM selection, which may help reduce epilepsy disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.